MaxCyte, Inc. (MXCT)
MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know
MaxCyte (MXCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share Price
MaxCyte, Inc. is rated a "Buy" due to significant upside potential despite recent share price declines. The company's core revenue is increasing and growth strategies have good prospects, driven by the strong growth of the global cell therapy market. Geopolitical tensions and a slowdown in the economy have hurt the share price, not problems in the company's business operations.
MaxCyte, Inc. (MXCT) Q4 2024 Earnings Call Transcript
Start Time: 16:30 January 1, 0000 5:12 PM ET MaxCyte, Inc. (NASDAQ:MXCT ) Q4 2024 Earnings Conference Call March 11, 2025, 16:30 PM ET Company Participants Maher Masoud - President and CEO Doug Swirsky - CFO Erik Abdo - IR Conference Call Participants Matt Larew - William Blair Julie Simmonds - Panmure Liberum Brendan Smith - TD Cowen Mark Massaro - BTIG Matt Hewitt - Craig-Hallum Operator Thank you for standing by and welcome to MaxCyte's Fourth Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.
MaxCyte: Building the Future of Cell and Gene Therapy Innovation
MaxCyte Inc. NASDAQ: MXCT is a global developer of next-generation cell therapies. They provide crucial technology for cell and gene therapies.
Recent Price Trend in MaxCyte (MXCT) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, MaxCyte (MXCT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
All You Need to Know About MaxCyte (MXCT) Rating Upgrade to Strong Buy
MaxCyte (MXCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
MaxCyte, Inc. (MXCT) Q3 2024 Earnings Call Transcript
MaxCyte, Inc. (MXCT) Q3 2024 Earnings Call Transcript
MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates
MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.11 per share a year ago.
MaxCyte (MXCT) Upgraded to Strong Buy: What Does It Mean for the Stock?
MaxCyte (MXCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Maxcyte: Reaching Financial Inflection With CASGEVY Ramp Up
MaxCyte, Inc.'s stock performance has been disappointing since its 2021 IPO, despite positive business developments and a 34% revenue growth. The company faces high capital requirements for modest revenue gains, but has a substantial cash reserve to sustain operations. FDA approval of CASGVEY validates MaxCyte's platform, with potential multi-billion dollar opportunities and significant future revenue.
MaxCyte, Inc. (MXCT) Q2 2024 Earnings Call Transcript
MaxCyte, Inc. (NASDAQ:MXCT ) Q2 2024 Earnings Call August 6, 2024 4:30 PM ET Company Participants Scott Feinberg - Investor Relations Maher Masoud - President and Chief Executive Officer Doug Swirsky - Chief Financial Officer Conference Call Participants Hannah Hefley - Stephens Julie Simmonds - Panmure Liberum Steven Mah - TD Cowen Matt Larew - William Blair Jack Siedow - Craig-Hallum Capital Group Paul Cuddon - Deutsche Numis Mark Massaro - BTIG Operator Ladies and gentlemen, thank you for standing by. Welcome to MaxCyte Second Quarter Earnings Conference Call.
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Tops Revenue Estimates
MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.10 per share a year ago.
